Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.45 – $38.33
73% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $111.0K | $0 | $0 | $0 | $0 | $0 | $34.0K |
| Gross profit | $0 | −$111.0K | $0 | $0 | $0 | $0 | $0 | −$34.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $10.1M | $36.5M | $24.6M | $38.5M | $48.2M | $23.8M | $10.8M | $201.2M |
| Operating income | −$12.9M | −$39.0M | −$33.6M | −$52.2M | −$61.2M | −$39.9M | −$22.3M | −$210.9M |
| EBITDA | −$12.9M | −$36.4M | −$34.6M | −$51.3M | −$60.7M | −$35.6M | −$21.1M | −$209.8M |
| Net income | −$15.9M | −$38.4M | −$34.8M | −$51.8M | −$61.6M | −$38.3M | −$21.4M | −$209.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -4.42 | -37.76 | -35.66 | -50.75 | -61.04 | -36.08 | -18.53 | -3.71 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.07 | $-1.07–$-1.07 | 2 |
| 2027 | $22M | $-1.48 | $-2.13–$-0.92 | 3 |
| 2028 | $77M | $-2.09 | $-2.58–$-1.60 | 2 |
| 2029 | $0 | $-2.53 | $-2.53–$-2.53 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds GLTO.
No tracked institution reports a position in GLTO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-08-30 | 1-for-25reverse |
No one on the platform has traded GLTO yet.
| $10M |
| — |
| BCDABioCardia, Inc. | $1.20 | +10.09% | $7M | — |
| INABIN8bio, Inc. | $1.36 | +0.00% | $13M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$GLTO decent data presented by $INCY for INCA033989 in ET/MF. However, DMR-001 has a possible edge due to activity in non-type 1 CALR mutations and ease of administration (SC versus IV).
View on StockTwits ↗$GLTO started a position. DMR-001 will build on the success of INCA033989 by $INCY and target both type 1 and non-type 1 CALR mutations with a more convenient administration (SC).
View on StockTwits ↗$GLTO so this changed to $DMRA but stocktwits don't know about it yet ?
View on StockTwits ↗$NEUP Both the $GLTO and $BRNS CEO's sent me similiar responses and then the deal was announced with 10 days of each of them...so assuming timing is always iffy. But this is a good, solid response. Thanks for sharing.
View on StockTwits ↗@BiotechValues why? I got similar emails from previous companies in strat alts. $BRNS emailed me 7 days before their deal announced, $GLTO 10 days before and most recently $RLYB only 6 days before.
View on StockTwits ↗@EZYME22 very nice. i wasn't even using AI i was just doing it based on my own knowledge so this is encouraging....if they find a good private company to merge w/ that agrees to continue the TRD program this is a win-win for all involved. $GLTO did this and went bonkers.
View on StockTwits ↗$GLTO Imagine a stock which is about to skyrocket but nobody is participating.
View on StockTwits ↗$GLTO lol this guy! Said it would never ever go past 25 ran to 38 unblocked me just to say this and then blocked me again. This novice made just over $5000 on its run to 38.🤪
View on StockTwits ↗$GLTO Galecto stock, watch for a bull flag breakout, target 42+ area
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.